Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2020

Open Access 01-12-2020 | Plasmodium Falciparum | Research

Artemether–lumefantrin treatment adherence among uncomplicated plasmodium falciparum malaria patients, visiting public health facilities in AsgedeTsimbla district, Tigray, Ethiopia: a cross-sectional study

Authors: Mekonnen Gebremichael Gebrekidan, Gebretsadik Berhe Gebremedhin, Yosef Sibhatu Gebregiorgis, Alefech Addisu Gezehegn, Kissanet Tesfay Weldearegay

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2020

Login to get access

Abstract

Background

Ethiopia has set a goal to eliminate malaria by 2030; Artemether–lumefantrine (AL) is put as one of the cornerstone strategies for uncomplicated plasmodium falciparum malaria treatment. However, only focusing on prescribing of the treatment without assessing patients’ adherence could lead to the resistance of the drug. In Ethiopia, there is limited evidence about patients’ adherence to AL and its influencing factors. Therefore, this study aimed at addressing this information gap.

Methods

A health facility based cross-sectional study was employed. Participants were selected using simple random sampling technique from registration books of the public health facilities in AsgedeTsimbla. Data were collected from March 24th to April 30th, 2018. We interviewed participants using a pre-tested structured questionnaire, and the blister pack was also inspected at their homes on day 4. Data were entered into Epi-Info and analyzed using SPSS 21. Odds ratios with 95% Confidence Intervals were estimated and the level of significance was declared at p-value ≤ 0.05.

Results

A total of 384 study participants were interviewed with a response rate of 95.5%. The overall AL adherence was 53.6% (95% CI 48.4–58.3%). Children aged < 5 years [AOR: 0.4, 95% CI (0.2–0.8)], and being treated in health post [AOR: 0.3, 95% CI (0.1–0.5)] were more likely to show AL adherence whereas illiteracy [AOR: 9.4, 95% CI (4.2–21.3)], didn’t know the consequence of discontinued AL [AOR: 4.0, 95% CI (2.1–7.6)], had concomitant drugs [AOR: 2.5, 95% CI (1.4–4.5)], and stopped/saved drug when improved before tablet got finished [AOR: 3.2, 95% CI (1.7–5.9)] were factors less likely to be associated with AL adherence.

Conclusion

AL adherence was low. Children aged < 5 years, and being treated in health post were determinants of AL adherence whereas illiteracy, didn’t know the consequence of discontinued the drug, had concomitant drugs, and stopped/saved drug when improved before tablet got finished were factors that hindered the AL adherence. Stakeholders should emphasize designing appropriate strategies including educational interventions to increase the AL adherence and prevent drug resistance. Further research should be conducted to evaluate AL resistance.
Literature
1.
go back to reference World Health Organization. “Antimalarial drug combination therapy. Report of a WHOtechnical consultation,”WHO/CDS/RBM 2001. Geneva, Switzerland; 2001. World Health Organization. “Antimalarial drug combination therapy. Report of a WHOtechnical consultation,”WHO/CDS/RBM 2001. Geneva, Switzerland; 2001.
3.
go back to reference World Health Organization. WHO | Guidelines for the treatment of malaria. Third edition. WHO. 2015. World Health Organization. WHO | Guidelines for the treatment of malaria. Third edition. WHO. 2015.
4.
go back to reference Ethiopian Federal Minstry of Health. Malaria case management training manual for health professionals in Ethiopia. Addis Ababa, Federal Minstry of Health: Participants Manual; 2016. Ethiopian Federal Minstry of Health. Malaria case management training manual for health professionals in Ethiopia. Addis Ababa, Federal Minstry of Health: Participants Manual; 2016.
5.
go back to reference Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, Kachur SP, Goodman CSD. Cluster randomized trial of text message reminders to retail staff in tanzanian drug shops dispensing Artemether–lumefantrine: Effect on dispenser knowledge and patient adherence. Am J Trop Med Hyg. 2014;91:844.CrossRef Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, Kachur SP, Goodman CSD. Cluster randomized trial of text message reminders to retail staff in tanzanian drug shops dispensing Artemether–lumefantrine: Effect on dispenser knowledge and patient adherence. Am J Trop Med Hyg. 2014;91:844.CrossRef
6.
go back to reference Ayalew MB. Therapeutic efficacy of Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: A systematic review and meta-analysis. Inf Dis Poverty. 2017;6:157.CrossRef Ayalew MB. Therapeutic efficacy of Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: A systematic review and meta-analysis. Inf Dis Poverty. 2017;6:157.CrossRef
7.
go back to reference Bruxvoort K, Goodman C, Patrick Kachur S, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9:84555.CrossRef Bruxvoort K, Goodman C, Patrick Kachur S, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9:84555.CrossRef
8.
go back to reference Anyanwu PE, Fulton J. Socioeconomic determinants of antimalarial drug use behaviours: a systematic review. J Commun Public Heal Nurs. 2016;2:123. Anyanwu PE, Fulton J. Socioeconomic determinants of antimalarial drug use behaviours: a systematic review. J Commun Public Heal Nurs. 2016;2:123.
9.
go back to reference Takahashi E, Nonaka D, Iwagami M, Phoutnalong V, Chanthakoumane K, Kobayashi J, et al. Patients’ adherence to artemisinin-based combination therapy and healthcare workers’ perception and practice in Savannakhet province. Trop Med Health: Lao PDR; 2018.CrossRef Takahashi E, Nonaka D, Iwagami M, Phoutnalong V, Chanthakoumane K, Kobayashi J, et al. Patients’ adherence to artemisinin-based combination therapy and healthcare workers’ perception and practice in Savannakhet province. Trop Med Health: Lao PDR; 2018.CrossRef
10.
go back to reference Ogolla JO, Ayaya SO, Otieno CA. Levels of adherence to coartem© in the routine treatment of uncomplicated malaria in children aged below five years, in Kenya. Iran J Public Health. 2013;42:129.PubMedPubMedCentral Ogolla JO, Ayaya SO, Otieno CA. Levels of adherence to coartem© in the routine treatment of uncomplicated malaria in children aged below five years, in Kenya. Iran J Public Health. 2013;42:129.PubMedPubMedCentral
11.
go back to reference Kalyango JN, Rutebemberwa E, Karamagi C, Mworozi E, Ssali S, Alfven T, et al. High Adherence to Antimalarials and Antibiotics under Integrated Community Case Management of Illness in Children Less than Five Years in Eastern Uganda. PLoS One. 2013. Kalyango JN, Rutebemberwa E, Karamagi C, Mworozi E, Ssali S, Alfven T, et al. High Adherence to Antimalarials and Antibiotics under Integrated Community Case Management of Illness in Children Less than Five Years in Eastern Uganda. PLoS One. 2013.
12.
go back to reference Lemma H, Löfgren C, San SM. Adherence to a six-dose regimen of Artemether–lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region. Malar J: Ethiopia; 2011.CrossRef Lemma H, Löfgren C, San SM. Adherence to a six-dose regimen of Artemether–lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region. Malar J: Ethiopia; 2011.CrossRef
13.
go back to reference MacE KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, et al. Adherence to treatment with Artemether–lumefantrine for uncomplicated Malaria in Rural Malawi. Clin Infect Dis. 2011;53:772.CrossRef MacE KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, et al. Adherence to treatment with Artemether–lumefantrine for uncomplicated Malaria in Rural Malawi. Clin Infect Dis. 2011;53:772.CrossRef
14.
go back to reference Aung W, Dondorp AM, Min M, Kyaw TT, Lawpoolsri S, Krudsood SSP. Assessment of adherence to three days course of Artemether–lumefantrine treatment in Rakhine state, Myanmar. JITMM Proc. 2015;4(3):16–23. Aung W, Dondorp AM, Min M, Kyaw TT, Lawpoolsri S, Krudsood SSP. Assessment of adherence to three days course of Artemether–lumefantrine treatment in Rakhine state, Myanmar. JITMM Proc. 2015;4(3):16–23.
15.
go back to reference Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP. Adherence to a six-dose regimen of Artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J. 2004;71:525. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP. Adherence to a six-dose regimen of Artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J. 2004;71:525.
16.
go back to reference Cohen JL, Yavuz E, Morris A, Arkedis J, Sabot O. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda. Malar J. 2012;11:83.CrossRef Cohen JL, Yavuz E, Morris A, Arkedis J, Sabot O. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda. Malar J. 2012;11:83.CrossRef
17.
go back to reference Afaya A, Salia SM, Opare FY, Ali S, Afaya RA. Patients’ adherence to antimalarial medication; self-report of patients at the Volta regional hospital of Ho. Int J Res Med Sci: Ghana; 2017.CrossRef Afaya A, Salia SM, Opare FY, Ali S, Afaya RA. Patients’ adherence to antimalarial medication; self-report of patients at the Volta regional hospital of Ho. Int J Res Med Sci: Ghana; 2017.CrossRef
18.
go back to reference Amponsah AO, Vosper H, Marfo AF. Patient related factors affecting adherence to antimalarial medication in an urban estate in Ghana. Mal Res Treat . 2015;2015:452539. Amponsah AO, Vosper H, Marfo AF. Patient related factors affecting adherence to antimalarial medication in an urban estate in Ghana. Mal Res Treat . 2015;2015:452539.
19.
go back to reference Onyango EO, Ayodo G, Watsierah CA, Were T, Okumu W, Anyona SB, et al. Factors associated with non-adherence to Artemisinin-based combination therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya. BMC Infect Dis. 2012;12:143.CrossRef Onyango EO, Ayodo G, Watsierah CA, Were T, Okumu W, Anyona SB, et al. Factors associated with non-adherence to Artemisinin-based combination therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya. BMC Infect Dis. 2012;12:143.CrossRef
20.
go back to reference Depoortere E, Guthmann JP, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, et al. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement. Trop Med Int Heal: Zambia; 2004.CrossRef Depoortere E, Guthmann JP, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, et al. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement. Trop Med Int Heal: Zambia; 2004.CrossRef
21.
go back to reference Siddiqui MR, Willis A, Bil K, Singh J, Mukomena Sompwe E, Ariti C. Adherence to Artemisinin Combination Therapy for the treatment of uncomplicated malaria in the Democratic Republic of the Congo. F1000Research. 2015. Siddiqui MR, Willis A, Bil K, Singh J, Mukomena Sompwe E, Ariti C. Adherence to Artemisinin Combination Therapy for the treatment of uncomplicated malaria in the Democratic Republic of the Congo. F1000Research. 2015.
22.
go back to reference Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014;13:7.CrossRef Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014;13:7.CrossRef
23.
go back to reference Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clinic Proceedings. 2011. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clinic Proceedings. 2011.
24.
go back to reference Medicines for Malaria Venture. Adherence to antimalarial treatments in the real world. Medicines for malaria venture: African health journal; 2015. Medicines for Malaria Venture. Adherence to antimalarial treatments in the real world. Medicines for malaria venture: African health journal; 2015.
25.
go back to reference Lam WY, Fresco P. Medication adherence measures: an overview. BioMed research international. 2015. Lam WY, Fresco P. Medication adherence measures: an overview. BioMed research international. 2015.
26.
go back to reference World Health Organization. Guidelines for the treatment of malaria. 313 p. World Health Organization. Guidelines for the treatment of malaria. 313 p.
28.
go back to reference Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O. Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in ethiopia. East Afr Med J. 2005;82:391.PubMed Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O. Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in ethiopia. East Afr Med J. 2005;82:391.PubMed
29.
go back to reference Office AH, Tsimbla A, district health report, . AsgedeTsimbla district health office: Endabaguna town. Ethiopia: Tigray; 2017. Office AH, Tsimbla A, district health report, . AsgedeTsimbla district health office: Endabaguna town. Ethiopia: Tigray; 2017.
30.
go back to reference Morisky DE, Green LWLD. Concurrent and predictive validity of a self-reported measure of medication adherence: Morisky 8-Item Medication Adherence Questionnaire. Med Care. 1986;24:64.CrossRef Morisky DE, Green LWLD. Concurrent and predictive validity of a self-reported measure of medication adherence: Morisky 8-Item Medication Adherence Questionnaire. Med Care. 1986;24:64.CrossRef
31.
go back to reference Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg. 2004;71:179.CrossRef Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg. 2004;71:179.CrossRef
32.
go back to reference Gore-Langton GR, Alenwi N, Mungai J, Erupe NI, Eves K, Kimwana FN, et al. Patient adherence to prescribed artemisinin-based combination therapy in Garissa County, Kenya, after three years of health care in a conflict setting. Malar J. 2015;14:125.CrossRef Gore-Langton GR, Alenwi N, Mungai J, Erupe NI, Eves K, Kimwana FN, et al. Patient adherence to prescribed artemisinin-based combination therapy in Garissa County, Kenya, after three years of health care in a conflict setting. Malar J. 2015;14:125.CrossRef
33.
go back to reference Bruxvoort K, Kalolella A, Cairns M, Festo C, Kenani M, Lyaruu P, et al. Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy? Malar J. 2015;14:87.CrossRef Bruxvoort K, Kalolella A, Cairns M, Festo C, Kenani M, Lyaruu P, et al. Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy? Malar J. 2015;14:87.CrossRef
34.
go back to reference Spilker B. Methods of assessing and improving compliance in clinical trials. Patient compliance in medical practice and clinical trials. New York: Ravan Press; 1991. Spilker B. Methods of assessing and improving compliance in clinical trials. Patient compliance in medical practice and clinical trials. New York: Ravan Press; 1991.
35.
go back to reference Bassat Q, González R, MacHevo S, Nahum A, Lyimo J, Maiga H, et al. Similar efficacy and safety of Artemether–lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malar J. 2011;10:369.CrossRef Bassat Q, González R, MacHevo S, Nahum A, Lyimo J, Maiga H, et al. Similar efficacy and safety of Artemether–lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malar J. 2011;10:369.CrossRef
37.
go back to reference Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, Ali D, Kachur SP, Mathanga DP, Skarbinski J. Adherence to treatment with artemetherlumefantrine for uncomplicated malaria in rural Malawi. Clin Infect Dis. 2011;53:772–9.CrossRef Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, Ali D, Kachur SP, Mathanga DP, Skarbinski J. Adherence to treatment with artemetherlumefantrine for uncomplicated malaria in rural Malawi. Clin Infect Dis. 2011;53:772–9.CrossRef
38.
go back to reference Minzi O, Maige S, Sasi P, Ngasala B. Adherence to Artemether–lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania. Malar J. 2014;13:267.CrossRef Minzi O, Maige S, Sasi P, Ngasala B. Adherence to Artemether–lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania. Malar J. 2014;13:267.CrossRef
39.
go back to reference Omari AA, Gamble CL, Garner P. Artemether–lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2006;2006:CD005965.PubMedCentral Omari AA, Gamble CL, Garner P. Artemether–lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2006;2006:CD005965.PubMedCentral
Metadata
Title
Artemether–lumefantrin treatment adherence among uncomplicated plasmodium falciparum malaria patients, visiting public health facilities in AsgedeTsimbla district, Tigray, Ethiopia: a cross-sectional study
Authors
Mekonnen Gebremichael Gebrekidan
Gebretsadik Berhe Gebremedhin
Yosef Sibhatu Gebregiorgis
Alefech Addisu Gezehegn
Kissanet Tesfay Weldearegay
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2020
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-020-00846-y

Other articles of this Issue 1/2020

Antimicrobial Resistance & Infection Control 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.